162 related articles for article (PubMed ID: 24495412)
1. Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling.
Sandanayake NS; Camuzeaux S; Sinclair J; Blyuss O; Andreola F; Chapman MH; Webster GJ; Smith RC; Timms JF; Pereira SP
BMC Clin Pathol; 2014 Feb; 14(1):7. PubMed ID: 24495412
[TBL] [Abstract][Full Text] [Related]
2. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.
Timms JF; Cramer R; Camuzeaux S; Tiss A; Smith C; Burford B; Nouretdinov I; Devetyarov D; Gentry-Maharaj A; Ford J; Luo Z; Gammerman A; Menon U; Jacobs I
Clin Chem; 2010 Feb; 56(2):262-71. PubMed ID: 20093557
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Novel Biomarker for Biliary Tract Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.
Kikkawa S; Sogawa K; Satoh M; Umemura H; Kodera Y; Matsushita K; Tomonaga T; Miyazaki M; Yokosuka O; Nomura F
Int J Proteomics; 2012; 2012():108609. PubMed ID: 22888427
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer.
Christensen TD; Maag E; Larsen O; Feltoft CL; Nielsen KR; Jensen LH; Leerhøy B; Hansen CP; Chen IM; Nielsen DL; Johansen JS
JHEP Rep; 2023 Mar; 5(3):100648. PubMed ID: 36699667
[TBL] [Abstract][Full Text] [Related]
5. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
[No Abstract] [Full Text] [Related]
6. [Preliminary study of MALDI-TOF mass spectrometry-based screening of patients with the NSCLC serum-specific peptides].
An J; Tang C; Wang N; Liu Y; Guo W; Li X; Wang Z; He K; Liu X
Zhongguo Fei Ai Za Zhi; 2013 May; 16(5):233-9. PubMed ID: 23676979
[TBL] [Abstract][Full Text] [Related]
7. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
[TBL] [Abstract][Full Text] [Related]
8. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
9. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.
Velstra B; Vonk MA; Bonsing BA; Mertens BJ; Nicolardi S; Huijbers A; Vasen H; Deelder AM; Mesker WE; van der Burgt YE; Tollenaar RA
J Cancer Res Clin Oncol; 2015 Mar; 141(3):531-41. PubMed ID: 25240825
[TBL] [Abstract][Full Text] [Related]
10. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry.
Umar A; Dalebout JC; Timmermans AM; Foekens JA; Luider TM
Proteomics; 2005 Jul; 5(10):2680-8. PubMed ID: 15892168
[TBL] [Abstract][Full Text] [Related]
11. A combination of serum leucine-rich α-2-glycoprotein 1, CA19-9 and interleukin-6 differentiate biliary tract cancer from benign biliary strictures.
Sandanayake NS; Sinclair J; Andreola F; Chapman MH; Xue A; Webster GJ; Clarkson A; Gill A; Norton ID; Smith RC; Timms JF; Pereira SP
Br J Cancer; 2011 Oct; 105(9):1370-8. PubMed ID: 21970875
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC).
Yang J; Song YC; Song TS; Hu XY; Guo YM; Li ZF; Dang CX; Huang C
J Clin Lab Anal; 2012 May; 26(3):148-54. PubMed ID: 22628229
[TBL] [Abstract][Full Text] [Related]
13. Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry: rapid identification of bacteria isolated from patients with cystic fibrosis.
Baillie S; Ireland K; Warwick S; Wareham D; Wilks M
Br J Biomed Sci; 2013; 70(4):144-8. PubMed ID: 24400425
[TBL] [Abstract][Full Text] [Related]
14. Individualized metabolic profiling stratifies pancreatic and biliary tract cancer: a useful tool for innovative screening programs and predictive strategies in healthcare.
Lee JH; Yu SE; Kim KH; Yu MH; Jeong IH; Cho JY; Park SJ; Lee WJ; Han SS; Kim TH; Hong EK; Woo SM; Yoo BC
EPMA J; 2018 Sep; 9(3):287-297. PubMed ID: 30174764
[TBL] [Abstract][Full Text] [Related]
15. Differentiation between Streptococcus pneumoniae and other viridans group streptococci by matrix-assisted laser desorption/ionization time of flight mass spectrometry.
Yahiaoui RY; Goessens WH; Stobberingh EE; Verbon A
Clin Microbiol Infect; 2020 Aug; 26(8):1088.e1-1088.e5. PubMed ID: 31811915
[TBL] [Abstract][Full Text] [Related]
16. Serum peptide profiling for potential biomarkers in early diagnosis of Escherichia coli bloodstream infection.
Ma Y; Chen C; Yang M; He S; Zhang K; Wang C
Cytokine; 2019 Aug; 120():71-77. PubMed ID: 31026733
[TBL] [Abstract][Full Text] [Related]
17. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.
Freed GL; Cazares LH; Fichandler CE; Fuller TW; Sawyer CA; Stack BC; Schraff S; Semmes OJ; Wadsworth JT; Drake RR
Laryngoscope; 2008 Jan; 118(1):61-8. PubMed ID: 18043497
[TBL] [Abstract][Full Text] [Related]
18. The Exploration of Peptide Biomarkers in Malignant Pleural Effusion of Lung Cancer Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry.
Xu J; Xu B; Tang C; Li X; Qin H; Wang W; Wang H; Wang Z; Li L; Li Z; Gao H; He K; Liu X
Dis Markers; 2017; 2017():3160426. PubMed ID: 28386154
[No Abstract] [Full Text] [Related]
19. Screening for potential serum-based proteomic biomarkers for human type 2 diabetes mellitus using MALDI-TOF MS.
Meng Q; Ge S; Yan W; Li R; Dou J; Wang H; Wang B; Ma Q; Zhou Y; Song M; Yu X; Wang H; Yang X; Liu F; Alzain MA; Yan Y; Zhang L; Wu L; Zhao F; He Y; Guo X; Chen F; Xu W; Garcia M; Menon D; Wang Y; Mu Y; Wang W
Proteomics Clin Appl; 2017 Mar; 11(3-4):. PubMed ID: 27863080
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of inter-day and inter-individual variability of tear peptide/protein profiles by MALDI-TOF MS analyses.
González N; Iloro I; Durán JA; Elortza F; Suárez T
Mol Vis; 2012; 18():1572-82. PubMed ID: 22736947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
